Repository logo
 
Publication

Evaluation of the Efficacy of Single Anastomosis Sleeve Ileal (SASI) Bypass for Patients with Morbid Obesity: a Multicenter Study

2020-03Journal article Open access
Simple item page
dc.contributor.authorMahdy, T
dc.contributor.authorEmile, SH
dc.contributor.authorMadyan, A
dc.contributor.authorSchou, C
dc.contributor.authorAlwahidi, A
dc.contributor.authorRibeiro, R
dc.contributor.authorSewefy, A
dc.contributor.authorBüsing, M
dc.contributor.authorAl-Haifi, M
dc.contributor.authorSalih, E
dc.contributor.authorShikora, S
dc.date.accessioned2020-09-14T21:01:36Z
dc.date.available2020-09-14T21:01:36Z
dc.date.issued2020-03
dc.description.abstractBackground: Single anastomosis sleeve ileal (SASI) bypass is a newly introduced bariatric and metabolic procedure. The present multicenter study aimed to evaluate the efficacy of the SASI bypass in the treatment of patients with morbid obesity and the metabolic syndrome. Methods: This is a retrospective, seven-country, multicenter study on patients with morbid obesity who underwent the SASI bypass. Data regarding patients' demographics, body mass index (BMI), percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), and improvement in comorbidities at 12 months postoperatively and postoperative complications were collected. Results: Among 605 patients who underwent the SASI, 54 were excluded and 551 (390; 70.8% female) were included. At 12 months after the SASI, a significant decrease in the BMI was observed (43.2 ± 12.5 to 31.2 ± 9.7 kg/m2; p < 0.0001). The %TWL was 27.4 ± 13.4 and the %EWL was 63.9 ± 29.5. Among the 279 patients with type 2 diabetes mellitus (T2DM), complete remission was recorded in 234 (83.9%) patients and partial improvement in 43 (15.4%) patients. Eighty-six (36.1%) patients with hypertension, 104 (65%) patients with hyperlipidemia, 37 (57.8%) patients with sleep apnea, and 70 (92.1%) patients with GERD achieved remission. Fifty-six (10.1%) complications and 2 (0.3%) mortalities were recorded. Most complications were minor. All patients had 12 months follow-up. Conclusions: The SASI bypass is an effective bariatric and metabolic surgery that achieved satisfactory weight loss and improvement in medical comorbidities, including T2DM, hypertension, sleep apnea, and GERD, with a low complication rate.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationObes Surg . 2020 Mar;30(3):837-845.pt_PT
dc.identifier.doi10.1007/s11695-019-04296-3pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/33300
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectObesidade Mórbida/cirurgiapt_PT
dc.subjectAnastomose Cirúrgicapt_PT
dc.subjectObesity, Morbid/surgerypt_PT
dc.subjectAnastomosis, Surgicalpt_PT
dc.titleEvaluation of the Efficacy of Single Anastomosis Sleeve Ileal (SASI) Bypass for Patients with Morbid Obesity: a Multicenter Studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage845pt_PT
oaire.citation.issue3pt_PT
oaire.citation.startPage837-845pt_PT
oaire.citation.titleObesity surgerypt_PT
oaire.citation.volume30pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mahdy - SASI 11695-019-04296-3.pdf
Size:
350.08 KB
Format:
Adobe Portable Document Format
Download

Collections

LS - LHAmadora - Artigos